MedTrace Logo

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

NCT03372044 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-04-17

No results posted yet for this study

Summary

An open-label study to understand the effect of different modified release and immediate release formulations on plasma PF-06865571 concentrations after single oral administration under fed conditions

Conditions

  • Healthy

Interventions

DRUG

PF-06865571 Immediate release suspension

Suspension

DRUG

PF-06865571 Slow release MR tablets

Modified release tablets

DRUG

PF-06865571 Fast release MR tablets

Modified release tablets

DRUG

PF-06865571 Immediate release tablets

Immediate release tablets

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2018-03-09
Completion
2018-04-04
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03372044 on ClinicalTrials.gov